Table 1:

Single Factor PK Interactions

Victim Drug	Drug Class	PK-mediators	Perpetrator	Mechanism	PK effect	Ref.
Midazolam	Benzodiazepine	CYP3A	Fluconazole	CYP3A inhibitor	↑ AUC 200–300%	[20]
Atorvastatin	Statin	CYP3A4 OATP1B	Rifampin	OATP1B inhibitor	↑ AUC 682%	[24]
			GFJ	CYP3A inhibitor	↑ AUC 250% (acid)	[143]
			GFJ	CYP3A inhibitor	↑ AUC 330% (lactone)	[143]
			SLCO1B1 poly.	↓ OATP1B1 function	↑ AUC 52% ↑ AUC 144% (acid)	[144]
Paritaprevir	Anti-viral	CYP3A OATP1B BCRP P-gp	Ritonavir	CYP3A4 and P-gp inhibitor	↑ AUC 4700%	[14]
			Cyclosporine	Potential CYP3A4 and OAT1B inhibitor	↑ AUC 72%	[145]
			Tacrolimus	NA	↓ AUC 43%	[145]
			Carbamazepine	CYP3A4 inducer	↓ AUC 70%	[146]
Simvastatin	Statin	CYP3A4 OATP1B1	GFJ	CYP3A4 inhibitor	↑ AUC 1600%	[36]
Aripiprazole	Antipsychotic	CYP2D6 CYP3A4	CYP2D6 poly.	↓ CYP2D6 activity	↑ AUC 50%	[44]
			Paroxetine	CYP2D6 inhibitor	↑ AUC 140%	[147]
			Fluvoxamine	CYP3A4 inhibitor	↑ AUC 60%	[147]
			Itraconazole	CYP3A4 inhibitor	↑ AUC 48%	[148]
Voriconazole	Anti-fungal	CYP2C19 CYP2C9 CYP3A4	CYP2C19 poly.	↑ CYP2C19 activity	↓ AUC 48%	[45]
Warfarin	Anticoagulant	CYP2C9	CYP2C9 poly.	↓ CYP2C9 activity	↓ clearance 90%	[47]
5-fluorouracil	Anti-cancer	DPD OAT2	DPYD poly.	↓ DPD activity	Accumulation	[55]
			Cimetidine	Unknown	↑ AUC 72%	[149]
Diflomotecan	Anti-cancer	CYP3A BCRP	ABCG2 poly.	↓ BCRP expression	↑ AUC 299%	[56]
Repaglinide	Anti-diabetic	OATP1B1 CYP2C8	Rifampin	CYP3A4 inducer	↑ AUC 57%	[80]

Abbreviations and symbols: AUC- area under the plasma concentration-time curve; PK- pharmacokinetics; Poly.- polymorphism; Ref.- reference(s);

^↑- increased;

^↓- decreased.